title: Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers.
abstract: The purpose of this study was to determine the pharmacokinetics and safety of eletriptan in different phases of the menstrual cycle. Female volunteers (n = 16) with a regular menstrual cycle (28 +/- 4 days) received a single oral dose of 80 mg eletriptan during each of the four cycle phases: phase 1 (menses), days 1 to 4; phase 2 (follicular), days 6 to 10; phase 3 (ovulatory), days 11 to 13; and phase 4 (luteal), days 21 to 24. Eletriptan plasma concentrations were determined from serial plasma samples taken during a 24-hourperiod after dosing. Blood pressure, pulse rate, and ECG measurements were performed at baseline, 1 and 24 hours after dosing. No significant differences between phases were observed for maximum plasma concentration (cmax, range of means = 188-234 ng/ml), time to maximum concentration (tmax, range of means = 1.8-2.5 h), or systemic exposure (area under the curve [AUC], range of means = 1194-1514 ng x h/ml). Although there was a statistically significant difference in the terminal phase elimination rate constant (kel) between phases 1 and2 (0.175/h vs. 0.158/h, p = 0.044), the corresponding difference in terminal phase half-life (t 1/2) (4.0 h vs. 4.4 h) was not considered to be clinicallyrelevant. No clinically relevant differences in blood pressure, pulse rate, or ECG were observed, and the incidence, nature, and severity of adverse events were similar in all phases. The different phases of the menstrual cycle had no clinically significant effect on the pharmacokinetics, safety, or tolerability of oral 80 mg eletriptan in healthy females.
authors.affiliation: Central Research Division, Pfizer, Inc, Groton, Connecticut 06340, USA.
authors.forename: A K
authors.initials: AK
authors.lastname: Shah
authors.forename: L
authors.initials: L
authors.lastname: Laboy-Goral
authors.forename: N
authors.initials: N
authors.lastname: Scott
authors.forename: T
authors.initials: T
authors.lastname: Morse
authors.forename: G
authors.initials: G
authors.lastname: Apseloff
mesh_terms: D000293:Adolescent; D000328:Adult; D000932:Antiemetics / Q000009:adverse effects* / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D004569:Electroencephalography / Q000187:drug effects; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006207:Half-Life; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000493:pharmacokinetics*; D007986:Luteinizing Hormone / Q000097:blood; D008597:Menstrual Cycle / Q000378:metabolism*; D011759:Pyrrolidines / Q000009:adverse effects* / Q000493:pharmacokinetics*; D013056:Spectrophotometry, Ultraviolet; D014363:Tryptamines
chemical_list: D000932:Antiemetics; D007211:Indoles; D011759:Pyrrolidines; D014363:Tryptamines; C115647:eletriptan; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone